Capricorn Fund Managers Dumps $18.4 Million Worth of Waystar Stock in Q1

Capricorn Fund Managers reduced its Waystar stake by 692,554 shares in Q1 2026, an estimated $18.38 million sale that cut the position’s quarter-end value by $23.08 million. After the transaction, Capricorn holds 45,709 shares worth $1.10 million, equal to 0.17% of its $641.43 million U.S. equity AUM. The filing is more a positioning update than a fundamental catalyst, though it may modestly affect sentiment around the recently listed healthcare software company.

Analysis

This looks less like a clean fundamental exit and more like a liquidity/position-sizing decision after a failed post-IPO momentum trade. The key second-order read is that a high-quality, cash-generative healthcare software name is being treated like a de-risking source rather than a core compounder, which often happens when a fund wants to rotate capital into higher-beta winners or lower-duration balance sheet names. That creates an overhang risk for any holder assuming the stock has already “priced in” the bad news.

The market setup is more important than the filing itself: a mid-cap SaaS/payments name with a de-rated multiple and weak relative performance can stay cheap for months if it remains outside the “AI winner” bucket and lacks a near-term re-acceleration catalyst. The real vulnerability is not demand destruction; it is multiple compression from being stranded between software and healthcare, where investors demand both growth and defensibility but are not yet willing to pay for either. If execution is merely fine, the stock can remain a value trap despite attractive cash flow optics.

The contrarian case is that this kind of ownership churn often marks the late stage of forced selling, not the beginning of fundamental deterioration. If revenue growth holds in the mid-teens and free cash flow conversion stays intact, the name could rerate sharply on any proof point that AI-enabled workflow monetization is translating into net retention or margin expansion. The asymmetry is that downside from here is more likely a slow bleed, while upside needs only one strong quarter or guidance raise to trigger a sharp multiple reset.

Key Decisions for Investors

• Avoid chasing the stock immediately; wait for either a post-earnings inflection or a stabilization in relative performance versus the SaaS basket over the next 4-8 weeks.
• If already long, hedge with a short-dated call spread sale or a partial overlay against a healthcare-software ETF proxy to protect against another 10-15% de-rating.
• For tactical upside, consider a small starter long only on a confirmed guidance raise; target a 2:1 reward/risk into the next earnings window if free cash flow and bookings remain intact.
• Pair trade idea: long higher-quality healthcare workflow software with clearer reacceleration, short the weaker de-rated SaaS name, for a 1-3 month relative-value trade if the market continues to punish mixed-growth software.